No Data
No Data
We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $68
JP Morgan Maintains Overweight on PTC Therapeutics, Lowers Price Target to $72
PTC Therapeutics Analyst Ratings
RBC Capital Adjusts PTC Therapeutics Price Target to $64 From $63, Maintains Outperform Rating
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $41 to $72
Unlock the Full List